Short answer
Charles River Laboratories (CRL) filed its Q1 2025 10-Q quarterly report on May 7, 2025 for the quarter ended Mar 29, 2025. Quarterly revenue was $984M (down 2.7% year over year) with net income of $25M.
Q1 2025 key financials · XBRL
- Revenue
- $984M
- −2.7% YoY
- Net income
- $25M
- −65.1% YoY
- Operating margin
- 7.6%
- EPS (diluted)
- $0.50
- −61.5% YoY
Source: XBRL data from the Charles River Laboratories (CRL) Q1 2025 10-Q on SEC EDGAR. USD.
Charles River Laboratories Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk from U.S. tariffs on imports from Vietnam, Mauritius, and China impacting supply chain and operating margin as of early April 2025
- Most updated risk: NIH policy reducing research grants for indirect overhead announced Feb 7, 2025, currently under preliminary injunction but with uncertain final outcome
- Regulatory risk: FDA 2025 plan to reduce animal testing in preclinical studies may materially affect demand for animal-based research services
- Operational risk: Potential demand reduction if drug approval processes are streamlined or regulatory requirements become less stringent globally
- Financial risk: Revenue exposure to government R&D funding volatility, especially NIH, affecting timing and level of client purchases in the RMS segment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Charles River Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.